A5048402159- Chemical synthesis and alkaloids
- Psychedelics and Drug Studies
- Treatment of Major Depression
- Neurotransmitter Receptor Influence on Behavior
- Mental Health Research Topics
- Tryptophan and brain disorders
- Digital Mental Health Interventions
- Intensive Care Unit Cognitive Disorders
- Personality Disorders and Psychopathology
- Diverse academic research themes
- Stress Responses and Cortisol
- Mental Health Treatment and Access
Brain and Cognition Discovery Foundation
2024-2025
University of Toronto
2023-2024
University Health Network
2023-2024
Toronto Western Hospital
2024
Antidepressants require several weeks for the onset of action, a lag time that may exceed life expectancy in palliative care. Ketamine has demonstrated rapid antidepressant effects, but been minimally studied cancer and care populations. Herein, objective was to determine feasibility, safety, tolerability preliminary efficacy intranasal racemic ketamine major depressive disorder (MDD) patients with advanced cancer. We conducted single-arm, open-label phase II trial at Princess Margaret...
Objective To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resistant depression participants not on antidepressants at screening to that discontinued antidepressant medications leading up receiving psilocybin-assisted psychotherapy (PAP). Methods Participants (n = 27) received least one accompanied by as part an exploratory analysis from open-label, randomized, waitlist-controlled clinical trial. The primary...
Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms suicidality. However, the efficacy safety of ketamine transitional age youth (TAY; 18-25) populations remains understudied.In this retrospective analysis, TAY patients (n = 52) receiving TRD were matched sex, primary diagnosis, baseline severity, resistance a general adult (GA) sample (age 30-60). Patients received four infusions over 2 weeks...